MX9707569A - Un metodo para el tratamiento de la degeneracion macular. - Google Patents

Un metodo para el tratamiento de la degeneracion macular.

Info

Publication number
MX9707569A
MX9707569A MX9707569A MX9707569A MX9707569A MX 9707569 A MX9707569 A MX 9707569A MX 9707569 A MX9707569 A MX 9707569A MX 9707569 A MX9707569 A MX 9707569A MX 9707569 A MX9707569 A MX 9707569A
Authority
MX
Mexico
Prior art keywords
macular degeneration
treatment
exudative
oxidant
onset
Prior art date
Application number
MX9707569A
Other languages
English (en)
Inventor
John E Repine
Original Assignee
John E Repine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by John E Repine filed Critical John E Repine
Publication of MX9707569A publication Critical patent/MX9707569A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)

Abstract

La degeneracion macular es una enfermedad del ojo relacionada con la edad para la cual no hay hasta la fecha un tratamiento conocido que haya mostrado ser efectivo en el tratamiento prevencion del ataque o progresion de la enfermedad. El tratamiento actual de la degeneracion macular no-exudativa (forma seca) está limitado a un diagnostico temprano y a un tratamiento complementario cuidadoso, mientras que el tratamiento sintomático de la degeneracion macular exudativa (forma humeda) incluye terapia de fotocoagulacion por láser, cirugía, radiacion de dosificacion baja (teleterapia) y terapias anti-oxidantes o anti-inflamatorias. La presente invencion está relacionada con un nuevo método para el tratamiento o prevencion del ataque o progresion de la degeneracion macular, el comprende la administracion periodica de una agente mejorador del glutation (GSH) solo o en conjuncion con al menos una terapia anti-oxidante o anti-inflamatoria, y posiblemente, en adicion, a uno o más de los tratamientos sintomáticos mencionados anteriormente.
MX9707569A 1995-04-06 1996-03-29 Un metodo para el tratamiento de la degeneracion macular. MX9707569A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/418,645 US5596011A (en) 1995-04-06 1995-04-06 Method for the treatment of macular degeneration
PCT/US1996/003642 WO1996031212A1 (en) 1995-04-06 1996-03-29 A method for the treatment of macular degeneration

Publications (1)

Publication Number Publication Date
MX9707569A true MX9707569A (es) 1997-12-31

Family

ID=23658985

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9707569A MX9707569A (es) 1995-04-06 1996-03-29 Un metodo para el tratamiento de la degeneracion macular.

Country Status (11)

Country Link
US (1) US5596011A (es)
EP (1) EP0819003A4 (es)
JP (1) JPH11503152A (es)
CN (1) CN1106842C (es)
AU (1) AU691108B2 (es)
CA (1) CA2216281A1 (es)
IL (1) IL117793A0 (es)
MX (1) MX9707569A (es)
TW (1) TW426520B (es)
WO (1) WO1996031212A1 (es)
ZA (1) ZA962692B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2136557B1 (es) * 1997-08-22 2000-07-01 Martinez Parra Aurelio Juan Producto para tratamiento de la queratitis seca.
US8198334B2 (en) * 1997-10-27 2012-06-12 Pathologica Llc Methods for modulating macrophage proliferation in ocular disease using polyamine analogs
US6251868B1 (en) * 1998-04-30 2001-06-26 Teijin Limited Method for treating a human immunodeficiency virus infection
US6379664B1 (en) 1998-09-29 2002-04-30 Board Of Regents University Of Nebraska-Lincoln Composition and method for the prevention and treatment of oxidative damage in ocular tissues
RU2144374C1 (ru) * 1998-11-23 2000-01-20 Закрытое акционерное общество "ВАМ" Способ получения композита окисленного глутатиона с cis-диаминодихлорплатиной и фармацевтических композиций на его основе, регулирующих метаболизм, пролиферацию, дифференцировку и механизмы апоптоза нормальных и трансформированных клеток
HUP0201437A2 (en) 1999-05-27 2002-08-28 Iams Company Process and product for enhancing immune response in companion animal using a combination of antioxidants
WO2001024794A1 (en) * 1999-08-09 2001-04-12 Webb-Waring Institute For Biomedical Research A method for the treatment of ocular oxidative stress
US6582721B1 (en) * 1999-09-17 2003-06-24 Alcon, Inc. Stable carotene-xanthophyll beadlet compositions and methods of use
US6573299B1 (en) 1999-09-20 2003-06-03 Advanced Medical Instruments Method and compositions for treatment of the aging eye
US6875165B2 (en) 2001-02-22 2005-04-05 Retinalabs, Inc. Method of radiation delivery to the eye
US7226766B2 (en) 2001-06-12 2007-06-05 University Of Iowa Research Foundation S-methylcysteine, S-ethylcysteine, and related S-alkylthiols as antagonists to the effects of S-nitrosothiols and nitric oxide
CA2459547A1 (en) * 2001-09-14 2003-03-27 N.V. Nutricia Method of increasing the presence of glutathione in cells
JP2005521707A (ja) * 2002-03-28 2005-07-21 オキシス インターナショナル， インコーポレイテッド 神経保護方法、組成物、およびそのスクリーニング法
US8557855B2 (en) * 2002-07-03 2013-10-15 Allergan, Inc. Methods of using ryanodine antagonists in treating neural injury
US7776907B2 (en) 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
DE602004027429D1 (de) * 2003-02-12 2010-07-15 Coherent Gmbh Elementensatz zur chirurgischen Ablation von Augengewebe
US20040180090A1 (en) * 2003-03-12 2004-09-16 Demarco Peter Treatment of macular degeneration
JP4694773B2 (ja) * 2003-06-06 2011-06-08 ロート製薬株式会社 粘膜適用液状組成物
WO2005079294A2 (en) * 2004-02-12 2005-09-01 Neo Vista, Inc. Methods and apparatus for intraocular brachytherapy
US7563222B2 (en) * 2004-02-12 2009-07-21 Neovista, Inc. Methods and apparatus for intraocular brachytherapy
US20050249820A1 (en) * 2004-05-04 2005-11-10 Akorn, Inc. Nutritional supplement for the treatment and prevention of macular degeneration
JP4756837B2 (ja) * 2004-06-03 2011-08-24 ロート製薬株式会社 プラノプロフェン含有組成物
AU2004320491A1 (en) * 2004-06-08 2005-12-22 Paola Ammannati Enzymatic treatment of retinitis pigmentosa and relevant pharmaceutical composition therefor in form of a kit
EP2277516A1 (en) 2004-06-23 2011-01-26 ReVision Therapeutics, Inc. Retinyl derivatives for treating ophtalmic conditions
CA2584396A1 (en) * 2004-11-04 2006-05-18 Sirion Therapeutics, Inc. Modulators of retinol-retinol binding protein (rbp)-transthyretin (ttr) complex formation
CN101072555B (zh) * 2004-12-08 2011-06-29 矫正诊疗公司 治疗与视黄醇有关的疾病的方法、分析和组合物
US8088773B2 (en) 2005-05-12 2012-01-03 The Texas A&M University System Therapeutic compositions and methods
UA81382C2 (en) * 2005-07-11 2007-12-25 Composition for treating retinol-related diseases by modulation of retinol binding
JP2009515655A (ja) * 2005-11-15 2009-04-16 ネオビスタ、インコーポレイテッド 眼内近接照射療法のための方法および装置
US8050477B2 (en) * 2006-02-01 2011-11-01 Koninklijke Philips Electronics N.V. Radiation therapy flanning procedure
US7282225B1 (en) 2006-09-27 2007-10-16 Occular Technologies, Inc. Composition and methods for improving retinal health
US9084803B2 (en) * 2007-06-29 2015-07-21 Board Of Trustees Of Northern Illinois University Therapeutic uses of glutathione mimics
ITMI20080003A1 (it) * 2008-01-02 2009-07-03 Alfredo Pulpito Composizioni per uso oftalmico
CA2724327A1 (en) 2008-06-04 2009-12-10 Neovista, Inc. Handheld radiation delivery system for advancing a radiation source wire
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
JP5518608B2 (ja) * 2010-07-09 2014-06-11 ロート製薬株式会社 粘膜適用液状組成物
WO2012135432A2 (en) * 2011-03-29 2012-10-04 Kemin Industries, Inc. Dyes for membranes and biological structures
CN102540500A (zh) * 2012-03-01 2012-07-04 吕伟东 Uvpc色觉矫正眼镜片及制作工艺
CN104768533A (zh) 2012-06-11 2015-07-08 马库克利尔公司 治疗性制剂和治疗方法
KR101423631B1 (ko) * 2012-08-17 2014-07-25 주식회사파마킹 에스-알릴엘-시스테인을 유효성분으로 포함하는 안질환 예방 또는 치료용 조성물 및 이를 포함하는 의약제제
KR102620997B1 (ko) * 2022-11-10 2024-01-04 주식회사 아이두젠 노각나무 추출물을 유효성분으로 포함하는 시력 보호용 또는 망막 질환의 개선 및 예방용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8512163D0 (en) * 1985-05-14 1985-06-19 Fujisawa Pharmaceutical Co Oxothiazolidine compound
US5156852A (en) * 1989-04-20 1992-10-20 La Haye Laboratories, Inc. Composition and method for combating macular degeneration
US5310764A (en) * 1992-05-08 1994-05-10 Steven Baranowitz Treatment of age related macular degeneration with beta-carotene
US5208249A (en) * 1992-08-20 1993-05-04 Clintec Nutrition Co. Method for stimulating intracellular synthesis of glutathione using esters of L-2-oxothiazolidine-4-carboxylate
WO1995003009A1 (en) * 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration

Also Published As

Publication number Publication date
IL117793A0 (en) 1996-08-04
CN1106842C (zh) 2003-04-30
WO1996031212A1 (en) 1996-10-10
TW426520B (en) 2001-03-21
ZA962692B (en) 1996-10-09
CA2216281A1 (en) 1996-10-10
CN1183720A (zh) 1998-06-03
AU5255296A (en) 1996-10-23
AU691108B2 (en) 1998-05-07
EP0819003A1 (en) 1998-01-21
EP0819003A4 (en) 1999-03-17
US5596011A (en) 1997-01-21
JPH11503152A (ja) 1999-03-23

Similar Documents

Publication Publication Date Title
MX9707569A (es) Un metodo para el tratamiento de la degeneracion macular.
TWI255713B (en) Method for treating meibomian gland disease
IN168514B (es)
WO2002064163A3 (en) Reduction or prevention of pdt related inflammation
MX9302038A (es) Metodo para el tratamiento del cancer por una terapia conjunta con derivados de 2-halometilideno y un agente antineoplasico especifico de fase m o fase s.
PT668763E (pt) Utilizacao de fenserina para a preparacao de medicamentos para tratar doencas do conhecimento
AU5029599A (en) Methods for eradication of nanobacteria
PL310476A1 (en) Application of lamotrigin in treating neuro-aids diseases
ATE249819T1 (de) Präparate zur äusserlichen anwendung zur behandlung von dermatosen
ES2017808A6 (es) Un metodo para prepara una composicion para inhibir el crecimiento indeseado o patologico de celulas o tejidos.
HK1037980A1 (en) Use of selegiline or desmethylselegiline for the manufacture of a medicament for treating wounds, burns or photodamage.
AU4220389A (en) Method for treating and preventing loss of bone mass
AU3401093A (en) Therapeutic agent for threatened abortion
Morison Combination of methoxsalen and ultraviolet B (UVB) versus UVB radiation alone in treatment of psoriasis: a bilateral comparison study
Del Regato Roentgen therapy of carcinoma of the skin of the eyelids
BR9916963A (pt) Bupropiona para tratamento de doenças virais
PT654267E (pt) Carcinoestaticos para terapia hormonal contendo dienogest como componente eficaz
Feuerman et al. Solcoderm in the treatment of solar and seborrheic keratoses
Tiffee et al. Multiple cutaneous leiomyomas: Report of a case
Dellon et al. Perifolliculitis capitis: surgical treatment for the severe case
Schrems et al. The effect of topically applied prostaglandin inhibitors on the laser-induced disruption of the blood aqueous barrier
Robert et al. Protracted ruthenium treatment of recurrent pterygium
Schröder et al. Occlusion of Stenon’s duct by prolamine: a possible treatment of chronic parotitis? Preliminary experience from animal experiments
Parkin et al. Basal cell carcinoma of the temporal bone
EP1043022A4 (en) Inhibitors of sodium ion absorption, accelerators of sodium ion excretion, and means for the prevention or treatment of diseases resulting from excessive consumption of table salt